Pharmacogenetic Associations Between Atazanavir/UGT1A1*28 and Efavirenz/rs3745274 (CYP2B6) Account for Specific Adverse Reactions in Chilean Patients Undergoing Antiretroviral Therapy
Background: Efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor, and atazanavir (ATV), a protease inhibitor, are drugs widely used in antiretroviral therapy (ART) for people living with HIV. These drugs have shown high interindividual variability in adverse drug reactions (ADRs). UGT1A...
Saved in:
Main Authors: | Daniela Poblete (Author), Fernando Bernal (Author), Gabriel Llull (Author), Sebastian Archiles (Author), Patricia Vasquez (Author), Leonardo Chanqueo (Author), Nicole Soto (Author), María A. Lavanderos (Author), Luis A. Quiñones (Author), Nelson M. Varela (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Hyperbilirubinemia in atazanavir treated HIV-infected patients: the impact of the UGT1A1*28 allele
by: Panagopoulos P, et al.
Published: (2017) -
Hyperbilirubinemia in atazanavir-treated human immunodeficiency virus-infected patients: the impact of the UGT1A1*28 allele
by: Naidoo A, et al.
Published: (2017) -
Preliminary Pharmacogenomic-Based Predictive Models of Tamoxifen Response in Hormone-dependent Chilean Breast Cancer Patients
by: Carla Miranda, et al.
Published: (2021) -
Editorial: Pharmacogenetics and Pharmacogenomics in Latin America: Ethnic Variability, New Insights in Advances and Perspectives: A RELIVAF-CYTED Initiative
by: Patricia Esperón, et al.
Published: (2022) -
Assessing the Occurrence and Influence of Cancer Chemotherapy-Related Pharmacogenetic Alleles in the Chilean Population
by: Gareth I. Owen, et al.
Published: (2024)